As our in vitro studies revealed expression changes of mesenchymal proteins, SNAIL and vimentin (Figure 2C), and of MMP-2 and MMP-9 on cancer cells treated with the combination of metformin and selumetinib (Figure 4), we also investigated whether the combination therapy blocks tumour metastatic behavior in vivo. The gene discussed is MMP2; the disease is cancer.